Across TCGA pan-cancer cohorts, SPOCD1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SPOCD1 data layer compared with 25 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPOCD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SPOCD1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.
LUAD are the cancer types where SPOCD1 mass-spec protein most reproducibly stratifies survival.